Latanoprost insert

Drug Profile

Latanoprost insert

Alternative Names: Eye-D® latanoprost insert; Subconjunctival latanoprost controlled release insert; VS 101 insert

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViSci
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glaucoma

Most Recent Events

  • 24 Jul 2017 Efficacy data from a phase I/IIb trial in Glaucoma released by BioLight Life Sciences
  • 07 Sep 2016 Latanoprost insert is still in phase I/II trials for Glaucoma in USA (Subconjunctival)
  • 30 Jun 2014 Phase-I/II clinical trials in Glaucoma in USA (Subconjunctival)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top